Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03896932
Other study ID # IVIG in PID
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2020
Est. completion date May 1, 2020

Study information

Verified date May 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)

2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :

- Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)

- Prevention of severe bacterial infection

- Improvement of general health(weight gain and mentality)

- Integration in to social live

3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).


Description:

Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .

A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.

A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .

An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .

Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .

Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 1, 2020
Est. primary completion date May 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria:

- Age group: children patients under 18 years.

- The study will include patient diagnosed as primary immunodeficiency disease (PID) in Assiut university hospital on standard IVIG therapy.

Exclusion Criteria:

- Patient has SCID.

- Patient with history of severe IVIG side effect.

- Patient with severe immunodeficiency and has severe disseminated infection.

- Patient with renal impairment

- Patient with hepatic cell failure

- Patient with endocrinal abnormalities

- patient with secondary immunodeficiency diseases

Study Design


Intervention

Other:
minipooled- Intravenous immunoglobulin(MP-IVIG)
The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.

Locations

Country Name City State
Egypt Faculty of Medicine Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007 Sep;27(5):497-502. Epub 2007 Jun 19. — View Citation

El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulié V, Adam J, Burnouf T. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23. — View Citation

Piguet D, Tosi C, Lüthi JM, Andresen I, Juge O; Study investigators. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol. 2008 Apr;152(1):45-9. doi: 10.1111/j.1365-2249.2008.03597.x. Epub 2008 Jan 28. — View Citation

Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a single-center study. J Clin Immunol. 2009 May;29(3):343-51. doi: 10.1007/s10875-008-9260-x. Epub 2008 Nov 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of MP-IVIG assessed by the incidence of acute Serious Bacterial infections(SBIs) The rate of Acute SBIs for each participant per 1 year will be assessed by questionnaire (Serious Bacterial Infections) include sign and symptoms of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess. 1 year
Primary Safty of MP-IVIG assessed by percentage of adverse Events Overall percentage of adverse events as hemolysis and anaphylaxis headache and other complains that occur during 72 hours of following an infusion of MP-IVIG will be assessed by1) vital sign(pulse,blood pressure,Respiratory rate and temprature 2)Hemolysis by hemoglobin level,LDH,billirubin level.2)lbetwen infusions by home diaries. 72 hour after adminstration of MP-IVIG and betwen infusions period
Primary Study the pharmacokinetics- MP-IVIG trough levels MP-IVIG trough level concentration values of serum total IgG pre the MP-IVIG infusion
(if applicable).
predose sample
Primary Study the pharmacokinetics MP-IVIG plasma concentration -time curve Blood samples for analysis of pharmacokinetics MP-IVIG plasma concentration -time curve were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Primary Study the pharmacokinetics MP-IVIG half-life Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Primary Study the pharmacokinetics MP-IVIG area under the curve Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Primary Study the pharmacokinetics MP-IVIG Cmax Blood samples for analysis of pharmacokinetics MP-IVIG Cmax were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Primary Study the pharmacokinetics of MP-IVIG-Tmax. Blood samples for analysis of pharmacokinetics MP-IVIG Tmax were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Primary Study the pharmacokinetics of MP-IVIG elimination rate constant(s). Blood samples for analysis of pharmacokinetics MP-IVIG elimination rate constant(s) were obtained and analysed (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
Secondary Compare efficacy of MP-IVIG vs standard IVIG by compare incidence of SBIs of both • Compare the efficacy of MP-IVIG to standard IVIG in children with Primary immunodeficiency disease (PID). 1 year
See also
  Status Clinical Trial Phase
Completed NCT04561115 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT04566692 - A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Phase 4
Completed NCT01465958 - Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Phase 4
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02881437 - IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Phase 4
Recruiting NCT06092528 - Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency N/A
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Completed NCT03907241 - CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL Phase 3
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Completed NCT02806986 - Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Completed NCT03339778 - The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations N/A
Enrolling by invitation NCT00895271 - Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Recruiting NCT03206099 - NIAID Centralized Sequencing Protocol
Completed NCT02503293 - A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Phase 4
Recruiting NCT03610802 - Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
Completed NCT03815357 - What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
Completed NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Not yet recruiting NCT02123615 - ASIS for GAMMAGARD in Primary Immunodeficiency Phase 1/Phase 2